Your browser doesn't support javascript.
loading
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Talukder, Rafee; Makrakis, Dimitrios; Lin, Genevieve Ihsiu; Diamantopoulos, Leonidas N; Dawsey, Scott; Gupta, Shilpa; Carril-Ajuria, Lucia; Castellano, Daniel; de Kouchkovsky, Ivan; Jindal, Tanya; Koshkin, Vadim S; Park, Joseph J; Alva, Ajjai; Bilen, Mehmet A; Stewart, Tyler F; McKay, Rana R; Tripathi, Nishita; Agarwal, Neeraj; Vather-Wu, Naomi; Zakharia, Yousef; Morales-Barrera, Rafael; Devitt, Michael E; Cortellini, Alessio; Fulgenzi, Claudia Angela Maria; Pinato, David J; Nelson, Ariel; Hoimes, Christopher J; Gupta, Kavita; Gartrell, Benjamin A; Sankin, Alex; Tripathi, Abhishek; Zakopoulou, Roubini; Bamias, Aristotelis; Murgic, Jure; Fröbe, Ana; Rodriguez-Vida, Alejo; Drakaki, Alexandra; Liu, Sandy; Lu, Eric; Kumar, Vivek; Lorenzo, Giuseppe Di; Joshi, Monika; Isaacsson-Velho, Pedro; Buznego, Lucia Alonso; Duran, Ignacio; Moses, Marcus; Barata, Pedro; Sonpavde, Guru; Wright, Jonathan L; Yu, Evan Y.
Afiliación
  • Talukder R; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
  • Makrakis D; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
  • Lin GI; Department of Epidemiology, University of Washington, Seattle, WA.
  • Diamantopoulos LN; Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
  • Dawsey S; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Gupta S; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
  • Carril-Ajuria L; Department of Medical Oncology, Hospital Universitario, Madrid, Spain.
  • Castellano D; Department of Medical Oncology, Hospital Universitario, Madrid, Spain.
  • de Kouchkovsky I; Division of Oncology, Department of Medicine, University of California, San Francisco, CA.
  • Jindal T; Division of Oncology, Department of Medicine, University of California, San Francisco, CA.
  • Koshkin VS; Division of Oncology, Department of Medicine, University of California, San Francisco, CA.
  • Park JJ; Division of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI.
  • Alva A; Division of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI.
  • Bilen MA; Winship Cancer Institute of Emory University, Atlanta, GA.
  • Stewart TF; Division of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.
  • McKay RR; Division of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.
  • Tripathi N; Division of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
  • Agarwal N; Division of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
  • Vather-Wu N; Department of Medicine, University of Iowa, Iowa City, IA.
  • Zakharia Y; Division of Oncology, Department of Medicine, University of Iowa, Iowa City, IA.
  • Morales-Barrera R; Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Devitt ME; Division of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
  • Cortellini A; Department of Surgery and Cancer, Imperial College London, London.
  • Fulgenzi CAM; Department of Surgery and Cancer, Imperial College London, London.
  • Pinato DJ; Department of Surgery and Cancer, Imperial College London, London.
  • Nelson A; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
  • Hoimes CJ; Division of Medical Oncology, Seidman Cancer Center at Case Comprehensive Cancer Center, Cleveland, OH; Division of Medical Oncology, Duke University, Durham, NC.
  • Gupta K; Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
  • Gartrell BA; Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
  • Sankin A; Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
  • Tripathi A; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
  • Zakopoulou R; Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  • Bamias A; 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  • Murgic J; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb.
  • Fröbe A; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb; School of Dental Medicine, Zagreb, Croatia.
  • Rodriguez-Vida A; Medical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain.
  • Drakaki A; Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
  • Liu S; Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
  • Lu E; Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
  • Kumar V; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Lorenzo GD; Oncology University of Molise and ASL, Salerno, Italy.
  • Joshi M; Division of Hematology/Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, PA.
  • Isaacsson-Velho P; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Division of Oncology, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Buznego LA; Hospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.
  • Duran I; Hospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.
  • Moses M; Deming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA.
  • Barata P; Deming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA.
  • Sonpavde G; Genitourinary Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Wright JL; Fred Hutchinson Cancer Center, Seattle, WA; Department of Urology, University of Washington, Seattle, WA.
  • Yu EY; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Clin Genitourin Cancer ; 20(6): 558-567, 2022 12.
Article en En | MEDLINE | ID: mdl-36155169
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2022 Tipo del documento: Article